| PSKY |
Report |
Total Revenue (Q2'26) |
IN-LINE |
pred ~$6.86B vs. cons $6.88B |
MEDIUM |
| PSKY |
Report |
Adjusted EBITDA (Q2'26) |
BEAT |
pred ~$0.98B vs. cons $0.95B |
MEDIUM |
| PSKY |
Report |
Adjusted EPS (Q2'26) |
BEAT |
pred ~$0.18 vs. cons $0.15 |
MEDIUM |
| PSKY |
Guide |
FY2026 Revenue guidance |
UNCHANGED |
guide ~$30.0B vs. cons $29.9B (FY2026) |
MEDIUM |
| PSKY |
Guide |
FY2026 Adjusted EBITDA guidance |
UNCHANGED |
guide ~$3.8B vs. cons $3.75B (FY2026) |
MEDIUM |
| PSKY |
Guide |
Q3'26 Revenue outlook (implied, incl. tough political-ad comp offset) |
LOWER |
guide ~$7.15B vs. cons $7.25B (Q3 2026) |
LOW |
| PSKY |
Guide |
WBD deal timeline / ticking fee commentary |
UNKNOWN |
guide ~no firm close date (targeting resolution by mid/late 2027) vs. cons prior Q3'26 target (deal timeline) |
LOW |
| PSKY |
Guide |
Paramount+ subscribers (Q2'26, ex hard-bundle exits) |
UNCHANGED |
guide ~flat QoQ (~+1.5M ex-bundle exits) vs. cons flat-to-slightly-up (Q2 2026) |
MEDIUM |
| PSKY |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
LOW |
| PSKY |
Return |
5-day cumulative residual |
-0.5% (FADE) |
An in-line-to-modest-beat quarter with reaffirmed FY26 guidance likely sparks a short relief rally given how depressed sentiment is on deal-litigation risk, but management's historical refusal to give concrete WBD deal/ticking-fee/trial-timeline color means the dominant overhang (frozen merger, growing ~$650M/quarter ticking fee, elevated pro forma leverage, S&P/Fitch negative watch) remains unresolved. Reaffirmed FY26 targets also imply a steep H2 acceleration in EBITDA/margin that raises out-period execution risk, so sell-side is likely to trim or hold estimates flat rather than raise them, and headline-driven WBD litigation news flow (trial scheduling, settlement talk, CNN divestiture speculation) will likely dominate price action within the week, fading the initial print-driven bounce. |
LOW |